new drugs
neurological diseases



Chronic neurological diseases afflict tens of millions people worldwide placing a significant health burden on patients and economic impact on society. The NEU² consortium has defined as its “core” endeavor, the development of novel therapies addressing neuro-degenerative conditions with a specific focus on multiple sclerosis (MS). Worldwide, approximately 2,5 million people suffer from MS, and projections indicate a steadily increasing prevalence of this disease, especially in developed countries. Although intensive efforts have been made to identify treatments, limited progress has been made to date. At best, the current generation of therapies is capable of delaying the progression of MS, albeit in a proportion of patients only and along with substantial adverse effects.

The NEU² consortium, with the support of the German Federal Ministry of Education and Research (BMBF), has created a public-private framework which uses biological, clinical and technological insights to identify and progress treatments for MS. 

Latest news and press releases


Fraunhofer IME intensiviert seine translationalen Forschungsarbeiten in der Indikation Multiple Sklerose mit 4 vom BMBF geförderten Projekten

Katalysiert wird die Zusammenarbeit unterschiedlicher akademischer Partner mit den Fraunhofer IME Einrichtungen und Biotechfirmen durch das Kompetenzkonsortium NEU2. read more …


Lophius Biosciences GmbH joins NEU² and receives substantial grant funding for the diagnosis and monitoring of multiple sclerosis

Lophius has joined the NEU² program with a project addressing the development of a novel blood-based diagnostic test for multiple sclerosis. read more …


Baliopharm GmbH joins NEU²

read more …

See all news and press releases.


Sponsored by:

and supported by: